Loading…
Loading…
PEL.NS (Piramal Enterprises Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PEL.NS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PEL.NS and 80,000+ other tickers.
See exactly how PEL.NS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PEL.NS and 80,000+ other tickers.
Piramal Enterprises Limited operates as a diversified conglomerate with a global presence across its financial services and pharmaceutical divisions, extending its reach to India, North America, Europe, and Japan. Its core operations are structured into Pharmaceutical Manufacturing & Services and Financial Services segments. The company's financial services arm provides a broad spectrum of funding solutions. This includes offering housing finance to individuals and various financing avenues for the real estate sector, such as private equity, structured credit, senior secured debt…
No recent news available.